FDA OKs Eltrombopag Indication for Adult, Pediatric Severe Aplastic Anemia
November 19th 2018The FDA expanded the label for eltrombopag (Promacta) to now include indication for adults and pediatric patients 2 years and older with severe aplastic anemia in combination with standard immunosuppressive therapy.
Read More
FDA Approves New Combination HIV Drug
November 18th 2018The FDA has approved lamivudine and tenofovir disoproxil fumarate (Temixys, Celltrion) tablets, 300 mg/300 mg in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 35 kg.
Read More
Eltrombopag Granted FDA Approval for Severe Aplastic Anemia
November 18th 2018he FDA has expanded the approval of eltrombopag (Promacta) in combination with standard immunosuppressive therapy (IST) to include newly diagnosed adult and pediatric patients 2 years and older with severe aplastic anemia.
Read More
FDA OKs Rifamycin for Travelers' Diarrhea Caused by Noninvasive E coli
November 17th 2018Rifamycin's effectiveness was shown in a randomized, placebo-controlled clinical trial during which the drug significantly reduced symptoms of travelers’ diarrhea in adults afflicted with the condition in Guatemala and Mexico.
Read More